We chose TOP2A because it is used for breast cancer diagnostics and because, as a target for anthracyclines and topoisomerase II inhibitors, it also has a direct predictive therapeutic value in many cancers [16, 44–47]. The gene discussed is TOP2A; the disease is breast cancer.